Roupen Odabashian, Oncologist at Abbotsford Regional Hospital and Cancer Centre, Founder at MeDucation AI, Podcast Host at OncoDaily, shared on LinkedIn:
“The US government is moving to restrict Chinese open-weight AI models like DeepSeek and Kimi after repeated distillation warnings. Federal agencies are already cracking down.
Whatever you think of the security argument, notice what this actually restricts: the free, downloadable, run-it-yourself tier of frontier AI. That tier matters more in medicine than almost anywhere else.
Hospitals in low-resource settings cannot pay per-token API prices. Researchers who need models on-premises for privacy reasons often reach for open weights first. A lot of clinical AI experimentation quietly runs on exactly the models now under scrutiny.
There is a real tension here. Distillation and security risks are legitimate concerns. But if the open-weight ecosystem narrows to a few Western labs, the cost floor of medical AI rises, and the countries that most need cheap clinical AI feel it first.
I keep wondering who is modeling the public-health cost of restricting open weights, not just the security benefit. Is anyone?
But I guess if we can use KimiK2 or GLM hosted on Amazon Bedrock, at least this is still helpful.”
Other articles featuring Roupen Odabashian on OncoDaily.